Registry Launched to Evaluate Farapulse PFA Technology for Atrial Fibrillation
The DISRUPT-AF Registry aims to gather real-world clinical data on the Farapulse Pulsed Field Ablation System for AF treatment.
Phase III
Cardiology / Atrial Fibrillation
Status
Initiated
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The launch of the DISRUPT-AF Registry is significant as it aims to collect real-world data on the Farapulse technology, which could shape treatment guidelines and influence market dynamics in the atrial fibrillation space. Monitoring the outcomes will be crucial for understanding competitive positioning and potential shifts in market share.
Recommended action
Humanexa recommends Monitor.
Analysis
Key milestones include interim results from the registry and any subsequent regulatory submissions based on the findings.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.